Codexis Inc. Overview
Codexis, Inc., a biotechnology company headquartered in Redwood City, United States, operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company is publicly traded on the Nasdaq with its financials reported in USD. As of August 28, 2025, Codexis’s close price stood at $2.73. The company’s market capitalization is valued at approximately $254.55 million.
Financial Highlights
Codexis has experienced significant fluctuations in its stock price over the past year. The 52-week high was recorded at $6.08 on December 10, 2024, while the 52-week low was $1.90 on April 6, 2025. The company’s price-to-earnings ratio is currently at -3.25, indicating a challenging financial performance in recent periods.
Business Focus
Codexis specializes in the development of biocatalysts, which are crucial for the pharmaceutical and fine chemicals industries. The company’s technology is designed to facilitate the scale-up and implementation of biocatalytic solutions, enhancing the efficiency and sustainability of manufacturing processes for its global clientele.
Market Position
Despite recent financial challenges, Codexis continues to play a vital role in the biotechnology sector by providing innovative solutions that support the production of pharmaceuticals and fine chemicals. The company’s focus on biocatalysis positions it as a key player in advancing sustainable manufacturing practices within the industry.
Conclusion
Codexis, Inc. remains committed to its mission of developing cutting-edge biocatalytic technologies. While the company faces financial hurdles, its strategic focus on biocatalysis and global market presence underscores its potential for future growth and contribution to the biotechnology sector.